论文部分内容阅读
为了比较沙利度胺加伊立替康与伊立替康单药治疗铂类耐药卵巢癌的疗效与毒性,对入选的38例患者分为沙利度胺组18例,接受伊立替康125mg/m2,d1、d8,每21d为1个周期,加沙利度胺100mg/d起步,逐渐加至200mg/d;对照组20例单用伊立替康。结果:38例患者可评估,沙利度胺组和对照组的客观有效率分别为27.8%和15.0%;疾病控制率分别为61.1%和35.0%;疾病进展时间分别为4.6和3.1个月;中位生存时间分别为13和10个月。初步研究结果提示,沙利度胺加伊立替康对比伊立替康单药治疗铂类耐药卵巢癌有更好的临床疗效,值得进一步进行临床试验。
In order to compare the efficacy and toxicity of thalidomide plus irinotecan and irinotecan monotherapy in the treatment of platinum-resistant ovarian cancer, 38 patients enrolled were divided into the thalidomide group of 18 patients receiving irinotecan 125mg / m2, d1, d8 every 21d for a cycle, plus thalidomide 100mg / d start, and gradually added to 200mg / d; control group of 20 patients with irinotecan alone. Results: In 38 patients, the objective effective rates of thalidomide group and control group were 27.8% and 15.0% respectively; the disease control rates were 61.1% and 35.0% respectively; the disease progression time was 4.6 and 3.1 months respectively; The median survival time was 13 and 10 months respectively. Preliminary results suggest that thalidomide plus irinotecan versus irinotecan monotherapy in the treatment of platinum-resistant ovarian cancer have a better clinical efficacy, worthy of further clinical trials.